Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Trading under the symbol ‘MTSR’, the company said it plans to use the funds to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA ... and Novo Nordisk’s semaglutide—by improving ...